Nasdaq:ITRM
Iterum Therapeutics plc
A clinical-stage biopharmaceutical firm developing novel therapies for rare neurological diseases with a cash-rich balance sheet supporting high-risk R&D initiatives.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe the company's pipeline for rare diseases will succeed, offering potential for massive returns upon regulatory approval given the high unmet medical need in orphan drug markets. The robust cash position and recent reduction in annualized losses suggest improved operational efficiency or successful cost management strategies that could extend the runway significantly.
Bear Case
The stock faces severe downside risk due to the lack of any revenue streams, with total liabilities exceeding assets indicating a fragile balance sheet reliant on continuous equity issuance. The substantial retained earnings deficit and negative operating profit highlight the inherent volatility and high burn rate typical of early-stage biotechs that have not yet validated their commercial potential.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for rare diseases, specifically targeting neurological conditions. The company operates primarily in the United States and Europe, leveraging proprietary technologies to advance its pipeline from preclinical discovery through clinical trials. With no current revenue generation, the firm relies entirely on financing activities to fund its extensive research and development efforts.
Analysis
Management Discussion
The company reported a net loss of $24.8M for the latest period, representing an improvement from $38.4M in 2023, yet still reflecting deep losses typical of clinical-stage biotech firms. Cash flow from operations was negative at $26.8M, largely offset by substantial cash flow from financing of $26.7M and investing activities of $18.2M, resulting in a net cash increase to approximately $24.2M.
Industry Overview
The rare disease therapeutic market is characterized by high R&D costs, long development timelines, and significant regulatory hurdles, but offers lucrative incentives through orphan drug designations. Companies in this space often operate at a loss for many years before achieving commercialization, requiring continuous capital markets access to sustain operations.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $30.4M | $47.5M | $18.7M |
| Operating Income | $-30.4M | $-47.5M | $-18.7M |
| R&D | $17.6M | $40.0M | $10.5M |
| G&A | $12.8M | $7.5M | $8.0M |
| Stock-Based Comp | $4.8M | $784.0K | $363.0K |
| Depreciation | $84.0K | $31.0K | $30.0K |
| Amortization | $1.7M | $1.7M | $254.0K |
| Other OpEx | $0 | $0 | $254.0K |
| Non-Operating Income | $-13.8M | $9.7M | $-5.8M |
| Interest Income | — | — | $789.0K |
| Pre-Tax Income | $-44.1M | $-37.8M | $-24.5M |
| Income Tax | $301.0K | $613.0K | $240.0K |
| Continuing Ops | $-44.4M | $-38.4M | $-24.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-44.4M | $-38.4M | $-24.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-44.4M | $-38.4M | $-24.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $62.4M | $25.6M | $24.8M |
| Cash & Equivalents | $21.1M | $6.1M | $24.1M |
| Marketable Securities | $39.7M | $17.9M | $0 |
| Inventory | $0 | $0 | $0 |
| Prepaid Expenses | $1.3M | $1.6M | $614.0K |
| Other Current Assets | $302.0K | $38.0K | $48.0K |
| Long-Term Assets | $4.4M | $663.0K | $19.8M |
| PP&E (Net) | $69.0K | $51.0K | $23.0K |
| Intangibles | $1.7M | — | $19.7M |
| Operating Leases | $1.8M | $549.0K | $65.0K |
| Other LT Assets | $831.0K | $63.0K | $-26.0K |
| Total Assets | $66.8M | $26.3M | $44.6M |
| Current Liabilities | $9.1M | $13.5M | $17.6M |
| Accounts Payable | $2.8M | $5.0M | $251.0K |
| Current Leases | $332.0K | $365.0K | $67.0K |
| Other Current Liab | $1.6M | $396.0K | $14.6M |
| Long-Term Liabilities | $29.8M | $19.1M | $31.1M |
| Long-Term Debt | $10.1M | $11.5M | — |
| LT Operating Leases | $1.3M | $188.0K | — |
| Other LT Liab | $18.4M | $7.5M | — |
| Total Liabilities | $38.8M | $32.7M | $48.7M |
| Shareholders' Equity | $28.0M | $-6.4M | $-4.1M |
| Retained Earnings | $-422.9M | $-461.3M | $-486.1M |
| AOCI | $-350.0K | $1.0K | $0 |
| Total L&E | $66.8M | $26.3M | $44.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-44.4M | $-38.4M | $-24.8M |
| Non-Cash Adjustments | $20.5M | $-9.5M | $5.4M |
| Working Capital Changes | $5.4M | $8.5M | $-7.4M |
| Cash from Operations | $-18.5M | $-39.3M | $-26.8M |
| Capital Expenditures | $62.0K | $13.0K | $2.0K |
| Cash from Investing | $14.0M | $23.3M | $18.2M |
| Debt Repayments | $2.3M | — | — |
| Cash from Financing | $-1.8M | $1.0M | $26.7M |
| FX Effect | $-50.0K | $-61.0K | $-75.0K |
| Net Change in Cash | $-6.4M | $-15.0M | $18.1M |
| Beginning Cash | $27.5M | $21.1M | $6.1M |
| Ending Cash | $21.1M | $6.1M | $24.2M |
Frequently Asked Questions
How does Iterum Therapeutics plc make money?
The company's financial profile indicates a single strategic focus on pharmaceutical research and development, evidenced by significant investments in research and development expenses of $10.5M against zero revenue from sales or licensing.
What are the main risks for ITRM?
Complete absence of commercial revenue creates total dependency on external capital raises which may not be available in volatile markets, significant accumulated retained earnings deficit of $486.1M indicating prolonged losses, dilution risk from recurring common share issuances of $26.7M, and high operating expenses of $18.7M without a proven commercial product.
What is ITRM's competitive advantage?
Access to proprietary intellectual property platforms for rare disease targets, strong cash position providing flexibility to fund long-term R&D cycles without immediate profitability pressure, and potential for high-value orphan drug market exclusivity.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.